These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 28639989)

  • 1. Use of expenditure analysis to enhance returns on investments in HIV services.
    Honermann B; O'Hagan R
    Curr Opin HIV AIDS; 2017 Sep; 12(5):494-500. PubMed ID: 28639989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculating indirect costs from international PEPFAR implementing partners.
    Honermann B; Sharp A; Sherwood J; Kshetry P; Jones A; O'Hagan R; Lazar L; Chandra C; Hoffmann T; Millett G
    PLoS One; 2018; 13(10):e0206425. PubMed ID: 30372464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smart cascades: using cost analysis to improve HIV care and treatment interventions to achieve global 95-95-95 goals.
    Cantelmo CB; Lee B; Dutta A
    Afr J AIDS Res; 2019 Dec; 18(4):350-359. PubMed ID: 31779567
    [No Abstract]   [Full Text] [Related]  

  • 4. Investing in HIV services while building Kenya's health system: PEPFAR's support to prevent mother-to-child HIV transmission.
    Dutta A; Wallace N; Savosnick P; Adungosi J; Kioko UM; Stewart S; Hijazi M; Gichanga B
    Health Aff (Millwood); 2012 Jul; 31(7):1498-507. PubMed ID: 22778339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of reaching the 90-90-90 targets: are current investments enough?
    Kates J; Wexler A; Dieleman J; Moses M; Stover J
    Curr Opin HIV AIDS; 2019 Nov; 14(6):509-513. PubMed ID: 31524657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The private sector role in HIV/AIDS in the context of an expanded global response: expenditure trends in five sub-Saharan African countries.
    Sulzbach S; De S; Wang W
    Health Policy Plan; 2011 Jul; 26 Suppl 1():i72-84. PubMed ID: 21729920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEPFAR's past and future efforts to cut costs, improve efficiency, and increase the impact of global HIV programs.
    Holmes CB; Blandford JM; Sangrujee N; Stewart SR; DuBois A; Smith TR; Martin JC; Gavaghan A; Ryan CA; Goosby EP
    Health Aff (Millwood); 2012 Jul; 31(7):1553-60. PubMed ID: 22778345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners.
    Vassall A; Compernolle P
    Health Policy; 2006 Nov; 79(1):1-15. PubMed ID: 16388874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach.
    Zakumumpa H; Bennett S; Ssengooba F
    BMC Health Serv Res; 2017 Jan; 17(1):65. PubMed ID: 28114932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries.
    Beck EJ; Santas XM; Delay PR
    AIDS; 2008 Jul; 22 Suppl 1():S75-85. PubMed ID: 18664958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivering pediatric HIV care in resource-limited settings: cost considerations in an expanded response.
    Tolle MA; Phelps BR; Desmond C; Sugandhi N; Omeogu C; Jamieson D; Ahmed S; Reuben E; Muhe L; Kellerman SE;
    AIDS; 2013 Nov; 27 Suppl 2():S179-86. PubMed ID: 24361627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis on funds application of community based organizations involved in HIV/AIDS response and government financial investment in China, 2014].
    Zhang G; Zhu YX; Wang P; Liu P; Li JF; Sha S; Yang WZ; Li H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):232-236. PubMed ID: 28260337
    [No Abstract]   [Full Text] [Related]  

  • 14. The way forward: maximizing our impact through shared responsibility and smart investments.
    Goosby E
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 2():S44-7. PubMed ID: 22772391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual indices for prioritizing investment in decentralized HIV services at Nigerian primary health care facilities.
    Fronczak N; Oyediran KA; Mullen S; Kolapo UM
    Health Policy Plan; 2016 Apr; 31(3):377-89. PubMed ID: 26363172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis and assessment of health programs.
    Prescott N; de Ferranti D
    Soc Sci Med; 1985; 20(12):1235-40. PubMed ID: 3927488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scoping review of cost benefit analysis in reproductive, maternal, newborn and child health: What we know and what are the gaps?
    Maitra C; Hodge A; Jimenez Soto E
    Health Policy Plan; 2016 Dec; 31(10):1530-1547. PubMed ID: 27371550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.
    Mugo NR; Ngure K; Kiragu M; Irungu E; Kilonzo N
    Curr Opin HIV AIDS; 2016 Jan; 11(1):80-6. PubMed ID: 26575147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and Cost-Effectiveness of Integrating HIV and Nutrition Service Delivery: Pilots in Malawi and Mozambique.
    Bergmann JN; Legins K; Sint TT; Snidal S; ; Amor YB; McCord GC
    AIDS Behav; 2017 Mar; 21(3):703-711. PubMed ID: 27094787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV and health systems: research to bridge the divide.
    Kruk ME
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 2():S120-3. PubMed ID: 21857295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.